EMA 'Dear Doctor' letter to fix Takeda's Velcade errors
This article was originally published in Scrip
The European Medicines Agency (EMA) is recommending the gradual withdrawal from the market of all medicines containing meprobamate, a sedative medicine that was a precursor of the benzodiazepines. The agency's Committee for Medicinal Products for Human Use (CHMP) made the recommendation after an EU review was triggered by the French authorities' decision in July 2011 to suspend marketing authorisations for oral versions of the drug.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.